Therefore, pharmacological targeting of the glucagon-like peptide-1 receptor (GLP-1R), a class B G protein–coupled receptor (GPCR) that increases insulin release in a glucose-dependent manner and also suppresses appetite, leading to weight loss, is an effective strategy against T2D (Graaf et al., 2016). Here, INS is linked to type 2 diabetes mellitus.